FDA Panel Votes In Favor of Replimune’s Melanoma Treatment

An FDA advisory panel voted 10-3 Thursday in favor of Replimune Group's (REPX) experimental melanoma therapy, overriding regulatory concerns about the design of the company's pivotal cancer trial. The vote came after what The Wall Street Journal described as a contentious meeting in which independent experts debated the trial's structure.

The panel's recommendation marks a critical step toward potential approval for Replimune's treatment, though FDA staff had previously flagged issues with the trial design. Advisory panels are not binding, but the FDA typically follows their guidance on drug approvals.

The 10-3 vote split suggests most experts believe the therapy's benefits outweigh concerns about the study methodology. Replimune is developing the treatment for melanoma, a skin cancer that accounts for the majority of skin cancer deaths despite representing only a small fraction of cases.

The FDA will make its final approval decision in the coming months. A green light would give Replimune its first commercial product and mark entry into a competitive melanoma treatment market.